Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Sunovion Pharmaceuticals Inc.
Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder
April 26, 2023
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America
April 03, 2023
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion Answers Is Named a J.D. Power 2022 Certified Customer Service Program℠
March 07, 2023
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
AMSA and Sunovion Neuroscience Peer Teaching Program Reaches More Than 500 Students Over Four Years
June 16, 2022
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion and Otsuka Initiate Phase 3 Clinical Development of Non-Racemic Amisulpride for the Treatment of People with Bipolar Depression
February 09, 2022
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion Answers Is Named a J.D. Power 2021 Certified Customer Service ProgramSM
October 12, 2021
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
September 30, 2021
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion Presents New KYNMOBI® (apomorphine sublingual film) Study Data at the International Parkinson and Movement Disorder Society (MDS) Congress 2021
September 10, 2021
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
September 02, 2021
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
AMSA and Sunovion Neuroscience Peer Teaching Program Reaches More Than 400 Students Over Three Years
June 30, 2021
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Sunovion Presents Data From Marketed and Late-Stage Development Psychiatric Compounds At The American Psychiatric Association (APA) Annual Meeting 2021
May 03, 2021
From
Sunovion Pharmaceuticals Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.